A 2024 study found late-stage cancer patients on a novel treatment hit a 72% response rate, 35 times higher than the standard 2% rate. Quality-of-life scores jumped 43-fold, and 95% had fewer side effects than before.
In our published 2024 paper, late stage cancer patients that were treated had a 72% response rate. That's 35 times higher than conventional care compared to the 2% palliative care that we saw in conventional oncology. That's a major improvement. Quality of life, which is a score I like the most here, improved by 43 times. And 95% of the patients had fewer side effects than their previous standard oncology. This is huge.
